We investigated the role of Akt and Erk1/2 as LPS intensely stimulates granulocyte/macrophage-colony-stimulating factor (GM-CSF) release, and neutralizing GM-CSF profoundly suppressed LPS-induced inflammation, suppressed expression and activity of lung proteases, significantly reduced GM-CSF and tumor ...
Blood 133:697–709 Temesgen Z, Assi M, Shweta FNU, Vergidis P, Rizza SA, Bauer PR, Pickering BW, Razonable RR, Libertin CR, Burger CD et al (2020) GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-cohort study. Mayo Clin Proc 95:2382–2394 Temesgen Z,...
SV-BR-1-GM is a GM-CSF secreting, antigen-presenting immortalized breast cancer cell line. We report its efficacy on CNS tumor regression.Methods:Post-hoc analysis of a subset of all advanced MBC patients with CNS/intracranial metastases from previous phase 1, 2, and an ongoing randomized ...
16 In this prospective trial, patients were also randomized to receive GM-CSF or placebo prior to induction therapy to determine the effect that induction therapy for AML had on efficacy and toxicity. Correlative laboratory studies were also performed to identify in vivo changes that may explain ...
SV-BR-1-GM, a GM-CSF secreting, antigen-presenting immortalized breast cancer cell line, has emerged as a post ADC solution (1) based on a different MOA. We now report the results of SV-BR-1-GM in ADC treated patients.Methods:Post-hoc analysis of an ongoing randomized Phase 2 ...
Martha Mayo *Dan Denney *BloodTimmerman JM, Vose J, Levy R, Mayo M, Denney D. Long-term follow-up of patients treated in a phase 2 trial with MyVax Personalized Immunotherapy (recombinant Id-KLH with GM-CSF) after chemotherapy as initial treatment for follicular non-Hodgkin's lymphoma [...